Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 14/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123935 | 0.80 | QPCT (1.00) | QPCTRXFP1ALDH1A1 | |
| SCHEMBL3639892 | 0.80 | QPCT (1.00) | QPCTKMT2AALDH1A1 | |
| SCHEMBL12713422 | 0.80 | QPCT (0.65) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL5120078 | 0.79 | QPCT (0.67) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL7889980 | 0.77 | ALDH1A1 (0.63) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL12713468 | 0.76 | QPCT (0.61) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL18883831 | 0.75 | QPCT (0.60) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL13236187 | 0.74 | MAPT (0.62) | QPCTMAPTMEN1KMT2ALMNA | |
| SCHEMBL5126792 | 0.73 | QPCT (1.00) | QPCT | |
| SCHEMBL12713416 | 0.73 | LMNA (0.63) | QPCTMAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | claimed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | claimed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034907-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2160389-B1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128982-A1 | THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267911-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885MAPT 1024/4885MEN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.